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ABBREVIATIONS 
WHO: World Health Organization  
HUA: Hospital Universitario Araba  
MF: Mycosis fungoides  
FMF: Folliculotropic mycosis fungoides  
PCGD-TCL: Primary cutaneous gamma-delta T-cell lymphoma  
SPTCL: Subcutaneous panniculitis-like T-cell lymphoma  
MRI: Magnetic Resonance Imaging  
PCMZL: Primary cutaneous marginal zone (MALT) lymphoma  
FNA: Fine-needle aspiration 
AITL: Angioimmunoblastic T-cell lymphoma  
HRS-cells: Hodgkin and Reed/Sternberg cells  
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1. ABSTRACT  
Background. The involvement of the skin in neoplastic lymphoproliferative disorders 
can occur either by an affectation secondary to a systemic neoplasm or by a primary 
affectation of the skin, which is considered a primary cutaneous lymphoma, a non-
Hodgkin lymphoma presenting in the skin with no evidence of extracutaneous disease 
at the time of diagnosis. Clinical and histological diagnosis of cutaneous 
lymphoproliferative disorders is a challenge in dermatopathology.  
Objective. The aim of this paper is to review a selection of cases of cutaneous 
lymphoma occurred during the past three years in the Hospital Universitario Araba 
(HUA), focusing on the clinical and pathological diagnostic workup as a whole, to try 
to meet the difficulties encountered and compare them with those found in the medical 
literature and highlight the importance of clinical and histological correlation. 
Methods. Four cases occurred in the HUA during 2015-2018 were selected and 
compared through a systematic review of cutaneous lymphoma diagnostic workup in 
articles published in online medical databases and journals.  
Results. Each case is exposed and analyzed, emphasizing the time elapsed from the 
first consultation of the patient to final diagnosis, the number of biopsies that each case 
required, the inquiries made to external centers to confirm the diagnoses and the 
intervention of different departments. The information found during the bibliographic 
review of each case is exposed.  
Conclusion. Clinical and pathological correlation is crucial and should be materialized 
in the development of sessions and the organization of interdisciplinary committees, 
in which the diagnosis of cutaneous lymphoma is addressed jointly by the departments 
involved.  
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2. INTRODUCTION 
The involvement of the skin in neoplastic lymphoproliferative disorders can occur 
either by an affectation secondary to a systemic neoplasm or by a primary affectation 
of the skin, which is considered a primary cutaneous lymphoma.  
The World Health Organization (WHO) defines primary cutaneous lymphomas as 
non-Hodgkin lymphomas presenting in the skin with no evidence of extracutaneous 
disease at the time of diagnosis. The revised classification of 2018 includes 18 
different subtypes of primary cutaneous lymphoma, representing a quite complex field 
with many sub-categories (Table 1) [2].  
 
Revised WHO Classification 2018  (%)* 
Cutaneous T-cell and NK cell lymphomas 
Mycosis fungoides 39 
Mycosis fungoides variants and subtypes 
• Folliculotropic mycosis fungoides 5 
• Pagetoid reticulosis <1 
• Granulomatous slack skin  <1 
Sézary syndrome 2 
Adult T cell leukemia/lymphoma <1 
Primary cutaneous CD30+ lymphoproliferative disorders 
• Primary cutaneous anaplastic large cell lymphoma 10 
• Lymphomatoid papulosis 15 
Subcutaneous panniculitis-like T cell lymphoma 1 
Extranodal NK/T cell lymphoma, nasal type <1 
Primary cutaneous peripheral T cell lymphoma, rare subtypes  
• Primary cutaneous gamma-delta T cell lymphoma  <1 
• Primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma (provisional) <1 
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• Primary cutaneous CD4+ small/medium-sized pleomorphic T cell lymphoproliferative 
disorder (provisional)  
3 
• Primary cutaneous acral CD8+ T cell lymphoma (provisional)  <1 
Primary cutaneous peripheral T cell lymphoma, not otherwise specified 2 
Cutaneous B cell lymphomas 
• Primary cutaneous marginal zone B cell lymphoma 7 
• Primary cutaneous follicle center lymphoma 12 
• Primary cutaneous diffuse large B cell lymphoma, leg type  4 
Table 1. Revised WHO Classification 2018: types of primary cutaneous lymphomas and frequencies. 
T-cell cutaneous lymphomas account for 75-80 percent of all primary cutaneous 
lymphomas. These are a group of neoplasms formed by T lymphocytes with a wide 
variety in clinical, histological and immunophenotypical presentation, as well as 
different prognosis [2,3,4]. Mycosis fungoides represents 39 percent of primary 
cutaneous T-cell lymphomas, being therefore the most frequent cutaneous lymphoma, 
followed by primary cutaneous CD30+ lymphoproliferative disorders, that encompass 
lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma, 
which represent 15 and 10 percent of cutaneous T-cell lymphomas, respectively [2,4,6].  
B-cell cutaneous lymphomas are a group of neoplasms formed by B lymphocytes that 
represent 25 percent of all primary cutaneous lymphomas. The three main types of B-
cell cutaneous lymphomas are primary cutaneous marginal zone lymphoma, primary 
cutaneous follicle center lymphoma and primary cutaneous diffuse large B cell 
lymphoma, leg type [2,3,4]. 
The skin may also be affected by a systemic process originated elsewhere, but present 
cutaneous involvement in its development. Both T-cell lymphomas/leukaemias and B-
cell lymphomas/leukaemias can present cutaneous involvement, being necessary to 
differentiate them from a possible primary cutaneous lymphoma. 
Clinical and histological diagnosis of cutaneous lymphoproliferative disorders is a 
challenge in dermatopathology. The arduousness of the process lies not only in 
differentiating a primary cutaneous process from a systemic disease, and adequately 
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identifying the subtype to which it belongs, but also in making an accurate differential 
diagnosis with other benign processes that may present similar features.  
The aim of this paper is to review a selection of cases of cutaneous lymphoma occurred 
during the past three years in the HUA, focusing on the clinical and pathological 
diagnostic workup as a whole, to try to meet the difficulties encountered and compare 
them with those found in the medical literature. Of all selected cases, three correspond 
to primary cutaneous lymphomas of different subtypes, these being mycosis 
fungoides, primary cutaneous gamma-delta T-cell lymphoma and primary cutaneous 
marginal zone (MALT) lymphoma; while the other is a systemic lymphoma with 
cutaneous involvement, from a subtype called T-cell follicular type lymphoma.  
3. METHODS  
This paper is a review of the diagnostic work up followed in four cases of cutaneous 
lymphoma by the services of Dermatology and Pathology in the HUA. 
3.1. STUDY DESIGN  
A bibliographic study on the clinical and pathological diagnostic work up of cutaneous 
lymphomas has been carried out, through the systematic review of articles published 
in online medical databases and journals.  
3.2. BIBLIOGRAPHIC RESEARCH 
The search was based on the literature available in PubMed, UpToDate, Elsevier and 
the New England Journal of Medicine databases. The articles used in this review were 
found in the databases cited between July 2018 and March 2019.  
The first part of the research was focused on the collection of information on the 
different classifications and types of cutaneous lymphomas known up to date. Once 
the clinical cases used in the review were selected, a more specific research was made 
about each type of cutaneous lymphoma that would be included in the review: mycosis 
fungoides, primary cutaneous gamma-delta T-cell lymphoma, primary cutaneous 
marginal zone (MALT) lymphoma and T-cell follicular type lymphoma. 
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Main criteria used for the election of articles of interest were the publication dates, 
being the articles of the last 10 years prioritized; the origin of the articles, trying to 
choose those published in journals of greater impact in Dermatology and 
Dermatopathology, such as the Journal of the American Academy of Dermatology, 
Dermatologic Clinics, Diagnostic Histopathology or Seminars in Diagnostic 
Pathology, among others; and articles signed by authors with extensive knowledge in 
the field, such as Rein Willemze, Lorenzo Cerroni, Santiago Montes Moreno, and 
others.  
3.3. SELECTION OF CASES  
Cases of cutaneous lymphoma diagnosed during the past three years (2015-2018) were 
compiled by the Pathology department, from Vitropathã (Vitro Group, Master 
Diagnostica S.L), which is an integrated system for the management of this department 
that covers all of the pathological anatomy workflow (case registration, pending and 
laboratory work management, carving, reporting and validation of reports). Thirty four 
cases were located and out of those, four were selected to be reviewed and described 
more profoundly.  
Criteria considered for the inclusion of those cases were, primarily, to reflect the 
clinical and pathological diagnostic difficulties found in cutaneous 
lymphoproliferative disorders and the importance in these cases of clinical correlation, 
being necessary to follow up the biopsies and, in some cases, to review the previous 
results due to changes in the clinical course of the patient. Some of these cases 
correspond to commonly found lymphomas in daily practice, such as mycosis 
fungoides, but others are part of infrequent subtypes.  
Of these selected cases, blocks and preparations were removed from the General 
Archive of Pathology.    
3.4. REVIEW OF CASES  
A critical lecture of articles describing clinical signs, frequent histological findings, 
immunophenotyping features, molecular characteristics and prognosis of each type of 
cutaneous lymphoma was made.  
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Each case was approached individually, approaching first the dermatologic and 
clinical examination through the reports obtained from the Dermatology department 
and then the histopathological remarks listed in the reports from the Pathology 
department.  
The review of the cases of Pathological Anatomy consisted in analyzing first the 
Hematoxylin-Eosin stains, deepening in the morphological study of the samples; the 
immunohistochemical analysis was then reviewed with the antibodies corresponding 
to the lymphoid population, T or B-cell according to the case.  
Finally, molecular studies carried out by the Molecular Pathology group of the HUA 
were reviewed. For the molecular diagnosis of T-lymphoma, a fragment of the VJ 
segment of the hypervariable region of the TCR gene was amplified and for the 
molecular diagnosis of B-lymphoma, the VDJ segments of the hypervariable region of 
the immunoglobulin heavy chain (IgH) were amplified, using the PCR technique and 
subsequent electrophoresis (Kit Master Diagnostica).  
Some photographs were taken and included in this research work, from both clinical 
lesions and histological samples, in order to complete the information and facilitate 
understanding of the content. Clinical photos were obtained from the photography 
archives of the Dermatology service and the histological photos were obtained through 
a Sysmexã slider scanner (Sysmex España S.L).  
3.5. COMPARISON WITH LITERATURE  
Difficulties found during the diagnostic workup of each case in this hospital were 
compared with those referred in the articles dedicated to cutaneous lymphoma found 
in medical literature that are included in the bibliography section.  
4. RESULTS  
In this section, the clinical and histopathological development of each selected case is 
presented, and the information found related to each case in the reviewed medical 
literature is detailed. Correlation between both is exposed later in the Discussion 
section. 
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4.1. MYCOSIS FUNGOIDES 
4.1.1. Case development  
In November 2012, a woman on her fifties consulted in the Dermatology department 
for a tumor lesion in the left inner thigh area, which measured 7x2cm, it was pink 
colored and infiltrated (Figure 1A). A punch biopsy of the lesion was performed and 
sent to the pathology laboratory, after clinical diagnostic guidance with the suspicion 
of cutaneous lymphoma, pseudolymphoma, squamous cell carcinoma, 
dermatofibrosarcoma or leiomyosarcoma. The morphological analysis found a 
fragment of skin that showed a diffuse lymphoid infiltrate, which occupied the 
papillary and middle dermis, with focal involvement of the epidermis. It showed 
lymphoid cells with irregular nuclear contours, with isolated mitosis and occasional 
eosinophils. Histopathological diagnosis was "skin with mycosis fungoides in plaque 
stage". The sample suggested cutaneous lymphoma and was sent to Valdecilla 
Hospital (Santander), where they confirmed the diagnosis.  
 
  
Figure 1. Mycosis Fungoides. Initial tumor pink-colored lesion, located in the inner thigh area (A) and 
involvement of the follicles in progression to folliculotropic mycosis fungoides (B).  
In December 2012, a new lesion in the right shoulder developed and, after clinical 
evaluation, a biopsy was performed. The biopsy showed an irregular and atypical 
lymphoid infiltrate with an intra-dermal nodular distribution, without evidence of 
epidermotropism (Figure 2). Immunophenotypic analysis showed positivity for CD3-
CD4 in 80 percent of the lymphoid component, CD8 in 30-40 percent of the lymphoid 
component, isolated positivity of CD30 and positivity for CD79a-CD20 in 10 percent 
of the lymphoid component (Figure 3, Figure 4, Figure 5). This was very similar to 
A B 
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the first biopsy but the depth of the infiltrate was more compatible with "mycosis 
fungoides in tumor stage". The patient was assessed by the Hematology department, 
where they ruled out systemic neoplasm through a bone marrow biopsy that showed 
no evidence of tumor involvement.  
 
   
Figure 2. Images corresponding to the skin biopsy performed in December 2012, stained with hematoxylin-
eosin. Panoramic view of shoulder skin (A) that shows an irregular and atypical lymphoid infiltrate with 
nodular distribution (B, C). Diagnosis was: "mycosis fungoides in tumor stage".  
 
   
Figure 3. Images corresponding to the skin biopsy performed in December 2012, in three different 
magnifications, submitted to CD3 markers, with clear positivity of the nodular lymphoid infiltrates.  
 
   
Figure 4. Images corresponding to the skin biopsy performed in December 2012, in three different 
magnifications, submitted to CD4 markers, with clear positivity of the nodular lymphoid infiltrates.  
A B C 
A B C 
A B C 
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Figure 5. Images corresponding to the skin biopsy performed in December 2012, in three different 
magnifications, submitted to CD8 markers, with little positivity of the nodular lymphoid infiltrates. 
In the course of the disease, she presented scorched and lichenified lesions on the back 
and, to a lesser extent, also in the abdomen, antecubital flexures and thighs. Due to 
those new clinical findings, in 2013 a new punch biopsy was performed. The new 
biopsy showed similar findings to the previous biopsies and perpetuated the diagnosis 
of "mycosis fungoides in a tumor stage". Among the biopsies performed, some lesions 
were not lymphoma, but rather non-tumoral skin lesions, such as concomitant 
folliculitis with the neoplastic process.   
In 2014, after PUVA treatment with poor results, new tumor lesions that occurred as 
grouped follicular patches and plaques appeared (Figure 1B). The dermatologist 
performed a biopsy which included skin annexes and abundant subcutaneous cellular 
tissue. It showed a superficial crust with epidermis of irregular thickness and dermal 
fibrosis of cicatricial aspect. An irregular lymphoid infiltrate was observed, 
surrounding the follicles and infiltrating the follicular epithelium, in the form of 
"Pautrier microabscesses". Immunophenotypic analysis found out positivity for CD3-
CD4 in 80% of lymphoid component, highlighting the infiltration of the follicular 
sheath; isolated CD30, CD79a and CD20 positive accompanying cells. 
Histopathological diagnosis was informed as "folliculotropic mycosis fungoides" 
(Figure 6, Figure 7).  
 
A B C 
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Figure 6. Images corresponding to the skin biopsy performed in 2014, stained with hematoxylin-eosin. A, 
B. Panoramic view of fragment of skin with annexes and abundant subcutaneous cellular tissue. C. 
Irregular and atypical lymphoid infiltrates surrounding a follicle and infiltrating the follicular epithelium. 
Diagnosis was "folliculotropic mycosis fungoides".  
 
  
Figure 7. Images corresponding to the skin biopsy performed in 2014, submitted to CD4 (A) and CD8 (B) 
markers, showing positivity for the first one among neoplastic lymphoid cells.  
After initiating treatment with interferon-a with partial response and important side 
effects, biopsies of new lesions appearing in the back and the occipital region were 
performed. Both biopsies were compatible with infiltration by the already known 
lymphoma; one of them was "mycosis fungoides in tumor stage" and the other 
corresponded to a "folliculotropic mycosis fungoides".   
In June 2015, the patient presented bilateral new mediastinal and hilar pathological 
lymphadenopathies, together with three new pulmonary micronodules on CT. The 
patient was referred to the Hematology service, with suspicion of dissemination of the 
primary cutaneous lymphoma. The lymphadenopathies showed uptake in PET-CT, so 
in order to categorize these lesions, a transbronchial biopsy (EBUS) was performed. 
A B C 
A B 
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Samples showed groups of small lymphocytes without atypia and cylindrical 
contaminating epithelial cells. No cells suspected of malignancy or granulomas were 
observed, not being possible to rule out sarcoidosis or dissemination due to cutaneous 
lymphoma. At that time, she also presented new subcutaneous lesions in the left thigh, 
whose biopsy showed non-necrotizing granulomas, occasionally confluent, delimited 
by a mild chronic inflammatory infiltrate. The study of SBP, Zielh Neelsen stain and 
Fite were negative. Molecular studies showed no clonal rearrangement for the TCR 
gene. The diagnosis was "non-necrotizing granulomatous inflammation of sarcoid 
type" with no infiltration due to lymphoma observed in this sample.  
In August 2015, she developed two new lesions in the abdomen and a biopsy was taken 
from one of them, revealing a fragment of skin where orthokeratosis in epidermis was 
observed, without evidence of epidermotropism. The underlying dermis was 
compromised by a dense and diffuse mononuclear infiltrate that affected the entire 
thickness of the punch, with occasional eosinophils intermixed. Medium-large cells 
with an irregular nucleus were spotted, some with a visible eosinophilic nucleolus. 
Additionally, there were some lymphocytes, most of which had an irregular nucleus. 
Immunophenotypic studies carried out showed that the atypical population of medium-
large cells expressed CD4 and CD5 with partial loss of CD3 and CD2 expression and 
complete loss of CD7 expression. Also, 40% of the cells expressed CD30 weakly. 
ALK-1 was negative. CD8 and CD79a were positive in the peripheral populations 
accompanying T and B lymphocytes, respectively. Histopathological diagnosis was 
"tumor mycosis fungoides transformed to a large cell, CD30-" (Figure 8, Figure 9). 
Given the long evolution of the case, as well as its clinicopathological interest, this 
biopsy was reviewed jointly with pathologists from the Clinic Hospital (Barcelona).  
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Figure 8. Images corresponding to the skin biopsy performed in August 2015, stained with hematoxylin-
eosin. A. Panoramic view of a skin fragment from abdomen. B, C, D. Increased view of diffuse lymphoid 
infiltrate with eosinophils intermixed and atypical large cells with irregular nuclei. Diagnosis was "mycosis 
fungoides transformed to a large-cell".  
 
 
 
 
 
 
A B 
C D 
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Figure 9. Images corresponding to the skin biopsy performed in August 2015. A, B. Panoramic and 
magnified view, respectively, of CD4 markers with evident positivity. C, D. Panoramic and magnified view, 
respectively, of CD7 markers, which show loss of positivity of neoplastic cells. E, F. Panoramic and 
magnified view, respectively, of CD8 markers with positivity in accompanying cells. G, H. Panoramic and 
magnified view, respectively, of CD30 markers, with weak positivity.   
A B 
C D 
E F 
G H 
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In recent years, biopsies taken after the appearance of new tumor lesions after different 
treatments (bexarotene, interferon, radiotherapy) perpetuated the diagnosis of 
"Mycosis fungoides transformed to large cell lymphoma, CD30-".  
4.1.2. Bibliography review 
Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell 
lymphoma, which clinically usually presents in form of patches, plaques or tumors and 
in more advanced stages may present extracutaneous disease, usually affecting the 
liver, spleen, lung and peripheral blood [6,7].  
Patches indicate any size skin lesion without significant elevation or induration, they 
are usually erythematous lesions, with a predilection for not exposed areas; plaques 
indicate any size skin lesion that is elevated or indurated, they are characterized by 
infiltrated, irregular and erythematous lesions; tumors indicate at least one 1-cm 
diameter solid or nodular lesion with evidence of depth and/or vertical growth, they 
are usually solitary and may remain stable for months or grow rapidly. Mucosal 
involvement has been described in advanced stages, as well as the appearance of 
erythroderma in approximately 15 percent of mycosis fungoides, which must be 
differentiated from Sèzary syndrome. Other less frequent signs that can appear in 
mycosis fungoides are vesicular or purpuric lesions, ichthyosiform skin, keratosis 
pilaris-like lesions, opportunistic infections or alopecia. One of the most frequently 
described symptoms in mycosis fungoides is pruritus [4,6,7].  
Histopathological characteristics of MF vary according to the stage of the disease. 
Early stages present a patchy lichenoid or band-like infiltrate in the papillary dermis, 
where small lymphocytes predominate. In this stage, epidermotropism may be spotted, 
but Pautrier's microabscesses are rare to find. Some findings that can facilitate 
diagnosis in this stage are haloed-lymphocytes, exocytosis, lymphocytes on the basal 
layer of the dermis, epidermal lymphocytes of a larger size than dermal lymphocytes, 
hyperconvoluted intraepidermal lymphocytes or areas of low spongiosis with 
numerous lymphocytes. Plaques show a dense lymphocyte infiltrate in the upper 
dermis, with marked epidermotropism and, in some cases, Pautrier's microabscesses. 
Although these are considered a classic pathognomonic finding of MF, they are usually 
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absent in early and tumor lesions. Tumors reveal a nodular or diffuse infiltrate that 
affects the entire dermis and, occasionally, the subcutaneous fat, with frequent 
transformation to large cell lymphoma. Large cell transformation is defined as the 
presence of large lymphocytes exceeding 25 percent of the infiltrate or of large 
lymphocytes arranged in nodules [6,7].  
Mycosis fungoides typically expresses an a/b T-helper phenotype: TCRb+, TCRg-, 
CD2+, CD3+, CD4+, CD5+, CD7-, CD8-, CD45Ro+, TIA1- and most are negative 
for cytotoxic markers. In tumor stage, lymphocytes may lose expression of CD2, CD3 
or CD5 and other less frequent phenotypes have been described, such as CD8+, 
CD4+/CD8+, CD4-/CD8- or CD56+. Expression of CD30+ has been described in 40-
50 percent of large-cell transformed MF, although isolated CD30+ cells are not 
uncommon in classical MF, increasing in number as the degree of the disease increases 
[5,6,7].  
Most part of MF present clonal rearrangement for the TCR genes, but in early stages 
it may be difficult to find clonal rearrangements, due to a scarce tumor infiltrate. 
Likewise, clonal rearrangements can occur in benign reactive processes [5,6,7].  
There are three subtypes of mycosis fungoides included in the revised 2018 WHO 
Classification: folliculotropic mycosis fungoides (FMF), pagetoid reticulosis and 
granulomatous slack skin. FMF presents with follicular papules, acneiform lesions, 
keratosis pilaris-like lesions, cysts or indurated plaques and tumors. FMF 
preferentially involves the head and neck, but cases of lesions on the trunk and limbs 
as the sole site of involvement have been described. Histologically, it is a variant of 
MF formed by atypical CD4 T-cells with epidermotropism, which surround the 
follicles and may or may not be accompanied by mucinosis.  Other inflammatory cells, 
such as plasma-cells or eosinophils, are abundant in the perivascular and perianexal 
spaces and large-cell transformation is not uncommon. FMF phenotype is the same as 
that of classical mycosis fungoides [8,9,10].  
Patients with limited classic MF have an excellent prognosis. In advanced stages, 
prognosis is poor, especially for those with skin tumors and/or extracutaneous 
dissemination. Early stage FMF has a favorable prognosis, similar to that of early 
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mycosis fungoides, with a five-year survival rate of 94 percent; but advanced-stage 
FMF presents a five-year survival rate of about a 69 percent. Lack of response to 
treatment, age over 60 years, elevated levels of lactate dehydrogenase and histological 
transformation are adverse prognostic data [4,8].  
4.2. PRIMARY CUTANEOUS GAMMA-DELTA T-CELL LYMPHOMA 
4.2.1. Case development  
In late 2015, a sixty-five-year-old woman was referred to the department of 
Dermatology for presenting a subcutaneous lesion on the inner side of the left thigh 
for two months (Figure 10A). She was asymptomatic and did not remember any 
traumatic background. Physical examination showed an erythematous plaque under 
which an indurated lesion of approximately one cm was palpated. A biopsy was taken 
and sent for evaluation to the laboratory with the clinical diagnostic suspicion of 
dermatofibroma.  
   
Figure 10. Primary cutaneous gd T-cell lymphoma, disease progression. Initial subcutaneous lesion in the 
inner area of the left thigh (A), nodular and ulcerated lesion in the left thigh with necrotic eschar (B), loss 
of tissue secondary to cytotoxicity of the lymphoma and debridement (C).  
Pathological study showed a hypodermic increase of fibrous tissue in the septa with 
presence of an associated inflammatory infiltrate of lymphocytes and macrophages 
with some giant multinucleated cells, without granulomas. The infiltrate affected the 
periphery of the lobules, with necrosis of adipocytes giving the diagnosis of "septal 
panniculitis" (Figure 11).  
 
A B C 
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Figure 11. Images corresponding to the skin biopsy performed in 2015, stained with hematoxylin-eosin, in 
different magnifications. They show increase of fibrous tissue in the septa, accompanied by inflammatory 
infiltrates of lymphocytes, macrophages and some giant multinucleated cells and necrosis of adipocytes. 
Diagnosis was "septal panniculitis".  
A month later (January 2016), the biopsied lesion had disappeared and five new 
subcutaneous and no-painful lesions appeared on the inside of both thighs and one in 
the right lumbosacral region. None of them was ulcerated, and the patient remained 
asymptomatic.  
In May 2016, new painful and indurated lesions appeared in thighs and abdomen, 
leaving a scab. A blood analysis was performed finding normal amylase and lipase, 
negative a1-antitrypsin, normal complement, negative FR, ANA and ENA, and 
Mantoux was negative as well. Due to changes in the clinical course of the patient, a 
new biopsy was performed and sent to the laboratory with clinical suspicion of septal 
panniculitis.  
The sample, a fragment of skin of the abdomen, revealed an epidermis with focal 
vacuolar change. In dermis, perivascular and perifollicular patchy infiltration and 
A B 
C D 
E F 
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edema were observed, focally interstitial with phenomena of nuclear fragmentation 
and increase in mucin deposits were also observed. The small dermal vessels showed 
prominent endothelium without fibrinoid necrosis. The adipose panniculus showed 
lobular and septal inflammation marked with histiocytes, lymphocytes and occasional 
polynuclear cells, also some granulomatous structures were identified, without giant 
cells or changes of necrosis. Ziehl technique was negative, SBP was negative as well 
and DNA extraction for mycobacterial PCR was also negative. There were no 
lymphoid accumulations in the adipose panniculus and no atypia was identified. This 
was summarized as a mixed panniculitis, predominantly lobular with interface 
dermatitis and deposit of dermal mucin, compatible with "lupus panniculitis" (Figure 
12). This sample and the first biopsy taken in 2015 were sent to the Salamanca Hospital 
in order to be valued by a reference dermatopathologist, where they confirmed the 
diagnosis.  
 
  
  
 
Figure 12. Images corresponding to the skin biopsy performed in May 2016, stained with hematoxylin-
eosin, in different magnifications. A. Panoramic view of fragment of skin from the abdomen. The adipose 
panniculus showed lobular and septal inflammation marked with histiocytes, lymphocytes and 
polynuclear cells, with some granulomatous structures (B, E), with interface dermatitis and deposit of 
dermal mucin (C, D). Diagnosis at that moment was "lupus panniculitis".  
A B 
C D 
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The patient returned to consultation in September 2016, presenting a nodular and 
ulcerated lesion on the left thigh, that had appeared in January, over which a necrotic 
ulcer showed up (Figure 10B). The patient complained of asthenia, sore throat and 
fever of 38ºC. Due to clinical and lesional changes, a new biopsy was performed and 
sent to the laboratory with clinical suspicion of lupus panniculitis.  
This biopsy, a fragment of skin of the left thigh showed a necrotic epidermal surface; 
the dermis was widened and widely occupied, with fibrosis and abundant 
inflammatory infiltrate of acute interstitial distribution, with sitriking phenomena of 
nuclear fragmentation. Some nuclei were discretely enlarged, with occasional 
hyperchromasia. Dermal vessels were affected, with transmural inflammation, without 
findings of frank fibrinoid necrosis. Isolated adipocytes surrounded by the changes 
described above were observed. No granulomatous structures were observed, PAS 
staining, colloidal iron and alcian blue did not provide data of interest. Histological 
diagnostic impression at this point was "dermal necrosis with accompanying vascular 
involvement". Because of the lack of pathological or clinical suspicion of lymphoma, 
no lymphoid markers were performed at that moment (Figure 13).  
 
 
 
 
Figure 13. Images corresponding to the skin biopsy performed in September 2016, stained with 
hematoxylin-eosin. Necrotic epidermal surface (A); dermis occupied by inflammatory infiltrate, with some 
hyperchromatic nuclei and affected vessels, with transmural inflammation (A, B, C). Diagnosis was 
"dermal necrosis with accompanying vascular involvement".  
B 
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The 26th September of 2016, the patient was admitted at the Emergency department, 
in charge of the Internal Medicine service, due to general deterioration and fever. She 
was treated with piperacilin-tazobactam and vancomycin was added in the absence of 
response. An MRI of the left thigh was requested and an involvement of subcutaneous 
cellular tissue and signs of myositis without abscess or osteomyelitis were observed. 
A CT scan was performed, but no suspicious images were seen, except for 
splenomegaly. The Hematology service ruled out hematological neoplasia, since the 
bone marrow biopsy requested was negative. The Traumatology service decided to 
debride the injury and refer the patient to the Plastic Surgery Department of Donostia 
Hospital (Donostia - San Sebastián). The samples taken at Donostia Hospital during 
the months of October and November 2016 showed chronic and acute inflammation 
or panniculitis, without evidencing neoplasia.  
During her stay in Donostia Hospital, she had to be transferred to the ICU, due to acute 
renal failure secondary to septic shock and DVT in the right internal iliac vein and left 
gonadal vein. She was placed on hemodialysis and another debridement of the lesion 
was performed (Figure 10C).  
After the development of a hemophagocytic syndrome, clinical services informed the 
Pathology department, that carried out an exhaustive review of all the biopsies and 
pieces obtained so far. Signs of atypia were observed in the lymphoid cellularity and 
new markers were performed with the result of positivity for CD2, CD3, CD56 and 
granzyme B, and loss of markers for CD4, CD5, CD7 and CD8. PD1, CD57, CD30 
and TIA-1 were negative. Ki67 proliferative index was 30 percent. HIS EBER was 
also negative (Figure 14). 
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Figure 14. Images corresponding to the reviewed biopsy performed in September 2016, submitted to 
different specific markers, which show positivity for CD3 (A), and loss of markers for CD4 (B), CD5 (C), 
CD7 (D) and CD8 (E). Ki67 proliferative index was 30 percent (F, G).  
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This review led to a change in the diagnostic orientation of the case, proposing the 
possibility of a lymphoproliferative process and, given the initial panniculitis and the 
clinicopathological course of the disease, the proposed entities were "primary 
cutaneous gamma-delta T-cell lymphoma" and "subcutaneous panniculitis-like T-cell 
lymphoma". Because more specific markers were needed, the samples were sent the 
30th November 2016 to the Valdecilla Hospital (Santander) for diagnostic 
confirmation. They confirmed the previous findings and the specific 
immunohistochemical study showed positivity of the atypical cells for CD3, CD56, 
Granzyme, Perforin, TCR gamma, Ki66 of 70%, with negativity for CD20, CD4, CD8, 
CD30, TCRbF1, PD1, EBV-LMP1 and EBER. Histopathological diagnosis was 
"subcutaneous thigh tissue with primary cutaneous gamma-delta T-cell lymphoma", 
confirming the diagnostic suspicion of our hospital.  
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Figure 16. Images corresponding to new specific markers applied to the previous biopsy, resulting in 
positivity of the atypical cells for CD3 (A), CD56 (F), Granzyme (I), Perforin (J), TCR gamma (L) and 
negativity for CD20 (D), CD4 (B), CD8 (C), CD30 (E), TCRbF1 (K), PD1, EBV-LMP1 (H) and EBER (G). 
In December 2016, the patient was transferred to the Hematology service of the HUA. 
When the Dermatologist assessed the patient, she was disoriented in time and space. 
The patient died days later. 
4.2.2. Bibliography review  
Primary cutaneous gd T-cell lymphoma (PCGD-TCL) is a neoplasm composed of a 
clonal proliferation of mature and activated gd T-cells, with a cytotoxic phenotype. 
PCGD-TCL is a rare lymphoma, accounting for <1 percent of all cutaneous 
lymphomas [3,4,10,11,19].  
PCGD-TCL predominantly affects adults, with an average age of diagnosis of 60 
years, although pediatric cases (12-15 years) have been described [3,4,10,11]. It presents 
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with ulcero-necrotic plaques, nodules or tumors that affect predominantly the 
extremities, although other sites may be involved [3,4,10,11,18,19,20]. Cases with MF-like 
or psoriasis-like erythematous and scaly patches, that later evolve into aggressive 
lesions with ulceration have been described [12]. Dissemination to mucosal and other 
extranodal sites is common, but lymph nodes, spleen and bone marrow are not 
involved usually [3,4,11,19]. Patients may present a hemophagocytic syndrome (25-30%), 
more particularly in those with panniculitis involvement, and accompanying B 
symptoms such as fever, night sweats and/or weight loss [3,4,5,11,18,19,20].  
Histologically, PCGD-TCL is characterized by presenting epidermotropic, dermal and 
subcutaneous histological patterns, solely or, more usually, in combination 
[3,4,5,10,11,18,19,20]. Epidermal involvement can go from a mild epidermotropism to 
marked pagetoid reticulosis-like infiltrates, which may associate with intraepidermal 
vesiculation and necrosis [11,19]. Dermal involvement can occur from mild perivascular 
to deep nodular to diffuse lymphoid infiltrates [18]. Subcutaneous involvement is 
characterized by infiltration of the fat lobes with focal involvement of the septa and 
rimming of individual adipocytes, in a way that may be confused with the 
subcutaneous panniculitis-like T-cell lymphoma (SPTCL), but it shows more 
accentuated infiltration of the dermis and/or epidermis [4,5,18,19,20]. Neoplastic cells are 
medium-large sized, with pleomorphic nuclei and coarsely clumped chromatin. 
Angiocentricity, angiodestruction and necrosis are common, due to the cytotoxic 
phenotype of this lymphoma [3,4,5,10,11,18,19,20]. Some reported features that could 
complicate the diagnosis of primary cutaneous gd T-cell lymphoma are mucin 
deposition, simulating lupus erythematosus, or subcutaneous infiltrates with minimal 
atypia and a histiocytic mixture, simulating a non-specific panniculitis, which 
eventually ends up showing more specific biopsy findings [10]. 
PCGD-TCL cells express a TCR gd+, TCR ab-, CD2+, CD3+, CD5-, CD7+/- and 
CD56+ phenotype, with marked expression of cytotoxic proteins, including Granzyme 
B, perforin and TIA1. Most cases are double negative for CD4 and CD8, although 
cases that express CD8 positivity have been described, as well as cases of TCR gd and 
TCR ab co-expression. Molecular studies typically show a monoclonal rearrangement 
of the TCR genes [3,4,5,10,11,18,19,20].  
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Primary cutaneous gd T-cell lymphoma is an aggressive lymphoma usually associated 
with therapy resistance and a median survival of 12-15 months. Some studies have 
shown that subcutaneous fat involvement have a poorer prognosis, although cases with 
indolent behavior have been reported [3,4,10,11,13,18].  
4.3. PRIMARY CUTANEOUS MARGINAL ZONE (MALT) LYMPHOMA 
4.3.1. Case development 
In July 2013, an eighty-eight-year-old man was referred to the Dermatology 
department for presenting pruritic lesions on the trunk, upper limbs and scalp that 
lasted two months (Figure 17). On examination, he presented indurated, 
erythematous-violaceous lesions, with a deep component, without epidermal 
involvement. The patient was afebrile and had no accompanying symptoms. In the 
blood analysis, he had high IgE levels, the rest being normal. Two biopsies were taken 
from the back and sent to the laboratory with the clinical differential diagnosis of 
prurigo, cutaneous lymphoma, pseudolyphoma, Hailey-Hailey disease and bullous 
pemphigoid disease.  
 
  
Figure 17. Cutaneous B-cell marginal zone lymphoma. Indurated, erythematous-violaceous lesions, with a 
deep component, without epidermal involvement (A, B).  
Histologic study showed two skin fragments that included skin adnexa and abundant 
subcutaneous cellular tissue. Both showed a lymphoid infiltrate of nodular, 
perivascular and periadnexal disposition, with exocytosis and isolated spongiosis 
without evident epidermotropism. No vasculitis or granulomas were present. 
Immunophenotypic analysis was positive for CD3 and CD4 in 80% of the cells, 
CD79a and CD20 were positive in more than 50% of the cells, CD30 was positive in 
A B 
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isolated cells, CD43 and BCL-2 were also positive, favoring the diagnosis of "primary 
cutaneous marginal zone (MALT) lymphoma" (Figure 18, Figure 19, Figure 20).  
 
  
  
  
Figure 18. Images corresponding to the skin biopsy performed in July 2013, stained with hematoxylin-
eosin, that included skin adnexa and subcutaneous cellular tissue, showing a lymphoid infiltrate of 
nodular, perivascular and periadnexal disposition, with exocytosis and isolated spongiosis.  
 
   
Figure 19. Images corresponding to the skin biopsy performed in July 2013, submitted to CD3 markers, 
that show clear positivity of neoplastic cells.  
B A 
C D 
E F 
B A C 
  
27 
   
Figure 20. Images corresponding to the skin biopsy performed in July 2013, submitted to CD79a markers, 
that reflect positivity in 50 percent of neoplastic cells.  
The patient was referred to the Hematology department to determine whether it was a 
primary cutaneous lymphoma or a cutaneous affectation secondary to a systemic 
lymphoma. The myelogram did not present significant morphological alterations. The 
bone marrow biopsy showed interstitial and nodular infiltration by a B CD79a and 
Pax5 positive lymphoma, which indicated infiltration of bone marrow by lymphoma, 
elevating diagnosis to a "primary cutaneous marginal zone (MALT) lymphoma, stage 
IV, due to skin and bone marrow involvement" (Figure 21).  
 
  
  
Figure 21. Images corresponding to the bone marrow biopsy, stained with hematoxylin-eosin, showing an 
interstitial and nodular lymphoid infiltrate (A, B) that presents Pax5 positivity (C, D).  
In December 2013, a new biopsy of the left frontal area was performed due to the 
development of a new papule, to rule out another type of lesion (basal cell carcinoma) 
and confirm it was a lymphoma lesion. The sample revealed a diffuse dermal lymphoid 
B A C 
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infiltrate, with a morphologic and immunohistochemical profile similar to the previous 
biopsy, compatible with the diagnosis of "primary cutaneous marginal zone (MALT) 
lymphoma".   
In September 2018, a biopsy of a new erythematous-violaceous nodular lesion on the 
right cheek was performed. Histological study showed dermal infiltration by a 
medium-sized lymphoid population, with irregular and atypical nuclei; focally 
monocytoid appearance, which was arranged in a nodular and diffuse pattern between 
collagen bands. It cleared the cutaneous annexes for the most part, and respected the 
papillary dermis and epidermis, reaching the reticular dermis in all its thickness. It was 
accompanied by some scattered eosinophils, and no accompanying plasma cells were 
identified. Immunohistochemical study showed positivity for CD20 and CD79a in 
tumor cells, with aberrant expression of CD43 and positivity for BCL-2; CD3 was 
positive in the accompanying T component. Diagnosis was "skin with morphological 
and immunohistochemical findings compatible with infiltration due to his primary 
cutaneous marginal zone (MALT) lymphoma, previously diagnosed" (Figure 22).  
 
  
  
Figure 22. Images corresponding to the skin biopsy performed in September 2018, stained with 
hematoxylin-eosin, which showed dermal infiltration by a medium-sized lymphoid population, with 
irregular and atypical nuclei, arranged in a nodular and diffuse pattern between collagen brands, 
compatible with infiltration by primary cutaneous marginal zone (MALT) lymphoma.  
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Until now, the patient has received treatment with Rituximab and Leukeran, and he is 
stable, with no dermatological lesions or clinical symptoms related to lymphoma.  
4.3.2. Bibliography review  
Primary cutaneous marginal zone (MALT) lymphoma (PCMZL) is an indolent B-cell 
lymphoma composed of neoplastic small B cells, plasma cells and reactive T cells. It 
accounts for 7 percent of all primary cutaneous lymphomas [3] and 30-40 percent of all 
primary cutaneous B-cell lymphomas [4]. It most commonly affects adults, with an 
average age at diagnosis of 55 years, with male preponderance [4, 26].  
PCMZL usually presents violaceous red papules, plaques or nodules, located on the 
trunk or upper extremities, that can be pruritic and seldom painful [3,4,24,25,26]. These 
lesions are more often multifocal, but may also be isolated. Lesions may wax and 
wane, and can undergo spontaneous regression, which has been associated with 
anetoderma [3,4]. Recurrences are common, present in 40 percent of cases, more 
frequently in patients with multiple lesions, but extracutaneous dissemination is 
exceptional [26]. In recent studies, this lymphoma has been associated with 
gastrointestinal disorders and autoimmune diseases, as well as with Borrelia 
burgdorferi infection in Europe [4,24].  
Histologically, PCMZL presents with nodular or diffuse lymphocytic infiltrates in the 
dermis, separated from the epidermis by a prominent narrow layer (Grenz zone) and 
can sometimes extend to the subcutaneous fat. The infiltrate is composed by small 
lymphocytes, plasma cells and follicles with reactive germinal centers, admixed with 
numerous reactive T cells. Plasma cells are frequently located in the periphery of the 
infiltrate and in the subepidermal compartment [3,4,5,24,25,26]. Dutcher bodies (PAS+, 
immunoglobulin containing, intranuclear inclusions) and Russel bodies 
(intracytoplasmic inclusions) may be observed [24,25]. It rarely shows colonization of 
follicular structures, lymphoepitelial lesions or transformation into a diffuse large B 
cell lymphoma [25].  
PCMZL neoplastic cells express positivity for markers CD19, CD20, CD22, CD79a 
and BCL-2; and express negativity for CD3, CD5, CD10, Cyclin D1 and BCL-6 
markers. Reactive germinal centers cells present a CD10, BCL-6 positive and BCL-2 
  
30 
negative phenotype. Plasma cells express CD138 and CD79a, but are negative for 
CD20 and present restriction of light chains in the immunohistochemical study in 70-
75 percent of cases [3,4,5,24,25]. Two subsets of primary cutaneous marginal zone 
lymphoma have been described: a heavy chain class-switched form (more frequent), 
and a non class-switched form. The first one expresses IgG, reveals abundant reactive 
T lymphocytes and few neoplastic B cells. The latter expresses IgM and is usually 
accompanied by a diffuse proliferation of B cells, expresses CXCR3 and is associated 
with Borrelia burgdorferi infection [3,4].  
The clonal rearrangement of heavy and light chain genes of immunoglobulins by PCR 
helps confirm the diagnosis [26]. In some cases, translocations t(14;18), t(3;14) and 
t(11;18) have been reported, but it is rare [25].  
Primary cutaneous marginal zone (MALT) lymphoma has a favorable prognosis, with 
a 5-year survival rate of >98 percent, although recurrences are common. 
Extracutaneous dissemination is rare, but more frequently appears in multifocal 
disease, non-class-switched form and in cases with transformation [3,4,25]. 
4.4. T-CELL FOLLICULAR TYPE LYMPHOMA 
4.4.1. Case development 
In March 2015, a sixty-year-old woman consulted in the Dermatology department for 
a generalized pruritus process in trunk, upper limbs and scalp, that lasted two years, 
despite treatment with antihistamines (Figure 23). She presented lymphopenia and a 
previously performed CT scan showed splenomegaly; therefore, she was being 
followed-up by the Hematology department. She started phototherapy treatment, but 
did not produce any improvement.  
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Figure 23.  T-cell follicular type lymphoma. Skin with signs of dryness and slight scratching marks (A, B).  
During the course of the disease, the patient presented a submental adenopathy, a 
PAAF was performed. Histological analysis showed lymphocytes in different 
evolutionary stages, histiocytes and non-necrotizing microgranulomatous formations. 
Immunophenotypical study was positive for CD68 and negative for CD30. At that 
point, the diagnosis was found negative for malignant cells, compatible with "non-
necrotizing microgranulomatous lymphadenitis".  
After several topical treatments, the patient returned to consultation in July 2017 due 
to worsening of the pruritus process. The submental adenopathy had increased in size, 
she continued with lymphopenia and, in the CT requested by Hematology, she 
presented with enlarged splenomegaly and multiple lymphadenopathies. Along with 
the Hematology service, the decision was to remove the adenopathy and analyze it to 
rule out a lymphoma. Also, three skin biopsies from the scapular area, neck and 
shoulder were performed and sent to the laboratory. Later in August, two submental 
nodes were removed by the Maxillofacial Surgery department.  
Histological study of the three cutaneous biopsies revealed in dermis, and varyingly 
affecting its entire thickness, an inflammatory infiltrate that formed non-necrotizing 
granulomas constituted by occasionally multinucleated histiocytes, which were 
surrounded by a lymphocyte corona. No atypia suggesting malignancy was observed 
in any of the three biopsies submitted. Immunohistochemical techniques PAS, 
Giemsa, Grocott, Silver methamine, Zielh and Fite were negative for identification of 
causal agent. Despite negativity, the process suggested an infectious process, DNA 
was extracted and sent to the Microbiology department for PCR for Leishmania and 
B A 
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atypical mycobacteria, being the result negative. Histological sections of submental 
lymph nodes showed abundant small granulomas, not necrotizing, sarcoid type and 
few eosinophils, that suggested the diagnosis of "non-necrotizing chronic 
granulomatous lymphadenitis" (Figure 24).  
 
 
  
Figure 24. Images corresponding to the submental-lymph node biopsy performed in 2015, stained with 
hematoxylin-eosin. Panoramic view of the ganglion (A), showing abundant microgranulomas not 
necrotizing, sarcoid type and a few eosinophils (B). In the magnified image, the lymphocytes surpass the 
ganglion capsule (C).  
In September 2017, other infectious processes were discarded and epicutaneous tests 
were performed, being these negative. In the month of October, due to the patient's 
torpid evolution, all the biopsies performed on the skin and lymph nodes were 
carefully reviewed and the case was presented in dermatopathology session, where a 
new diagnostic orientation of the case was proposed. The possibility of a 
lymphoproliferative process accompanied by granulomas was suggested. Given the 
histological characteristics observed during the review of the case, 
"angioimmunoblastic T-cell lymphoma" was thought to be a possible diagnosis and 
new analysis were performed. Immunohistochemical study showed expression of 
CD3, partial CD4, PD1, BCL6 and partial CD7 expression by neoplastic cells. No 
expression of CD8 or CD10 were observed. EBV-EBER was negative and follicular 
dendritic cell expansion was not observed.  
Samples were sent to Valdecilla Hospital (Santander), reference center in the diagnosis 
of lymphomas, for extension of special techniques battery that could confirm or rule 
out the diagnostic suspicion. In this center, more specific immunohistochemical 
markers were added and lymphoma was confirmed: "lymph node with peripheral 
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lymphoma of follicular T-cell phenotype"; "skin with infiltration by T-cell follicular 
lymphoma". Both presented clonal rearrangement for the TCR-gamma gene.  
In November 2017, an iliac crest biopsy was performed, revealing nodular infiltration 
by a T-cell lymphoma, accompanied by microgranulomas (Figure 25).  
  
  
  
Figure 25. Images corresponding to the bone marrow biopsy performed in November 2017, stained with 
hematoxylin-eosin. Overview of bone barrow (A), showing an infiltration similar to that found in the skin 
biopsy, with nodular infiltration by a T-cell lymphoma (B, C, D), accompanied by microgranulomas (E, F).  
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The patient remains currently stable, although she continues with itching associated 
with the neoplastic process.   
4.4.2. Bibliography review  
Nodal T-cell lymphomas are a heterogeneous group of neoplasms, which include the 
subtypes of angioimmunoblastic T-cell lymphoma (the most frequent), T-cell 
follicular type lymphoma and nodal peripheral T-cell lymphoma with T-follicular 
helper phenotype, no otherwise specified. These last two subtypes were included in 
the 2016 WHO Classification as provisional entities [3].  
T-cell follicular type lymphoma is a node-based lymphoid neoplasm of T-follicular 
helper cells, with a predominantly follicular growth pattern lacking characteristic 
features of angioimmunoblastic T-cell lymphoma [29].  
This rare lymphoma can present with lymphadenopathies, hepatosplenomegaly and 
cutaneous rash, as well as laboratory abnormalities similar to those produced by 
angioimmunoblastic T-cell lymphoma. However, unlike the latter, cases with limited 
disease and absence of B symptoms have been reported [29].  
T-cell follicular type lymphoma is characterized by follicular or perifollicular growth 
of neoplastic cells with T-helper phenotype, and lacks diffuse polymorphic infiltration 
and vascularization, characteristic features of angioimmunoblastic T-cell lymphoma 
[4]. Also, large B-cells may be seen, including HRS-like cells [29].  
Immunophenotypic studies reveal the expression of at least two of the following 
markers: PD1, CD10, BCL6, CXCL13, ICOS, SAP and CCR5. Of these, PD1 and 
ICOS present >90 percent sensitivity, but are not specific since may also be present in 
activated T-cells. On the other side, CXCL13 and CD10 are more specific markers for 
T-cell follicular type lymphoma [4, 29]. Large B-cells in interfollicular areas usually 
express pan-B markers and are EBV+. HRS-like cells express CD30+ and are usually 
EBV+, although they may be EBV- and rosetted by neoplastic T-follicular helper cells. 
Molecular analysis shows clonal rearrangement of TCR genes, and approximately 20 
percent of cases harbor a t(5;9) translocation [29].  
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Recent studies about T-cell follicular type lymphoma have shown that the behavior 
was aggressive, with 50 percent of patients dying after a median follow up of 24 
months [29]. 
4.5. GLOBAL STUDY OF ALL CASES 
4.5.1. Time elapsed to final diagnosis 
 
Figure 26.  Time elapsed from first consultation until histological final diagnosis. Mycosis fungoides 
transformed to large-cell lymphoma: 34 months; Primary cutaneous gamma/delta T-cell lymphoma: 12 
months; Primary cutaneous marginal zone (MALT) lymphoma: 2 months; T-cell follicular type lymphoma: 
31 months.  
The diagnosis of classic MF was obtained from the first biopsy, but the clinical picture 
was evolving, ending in a folliculotropic mycosis fungoides transformed into a large-
cell lymphoma (CD30-), which was diagnosed 34 months after the patient's first 
consultation. Primary cutaneous gamma-delta T-cell lymphoma, which is a rare 
lymphoma, happened with a rapidly progressive clinical picture and the diagnosis was 
delayed for 12 months. In the case of primary cutaneous marginal zone (MALT) 
lymphoma, the diagnosis required 2 months, less than in the rest of cases. T-cell 
follicular type lymphoma, an extremely rare lymphoma, recently included in the WHO 
Classification, delayed the diagnosis for 31 months. 
 
0 5 10 15 20 25 30 35 40
Mycosis fungoides transformed to large-cell lymphoma
Primary cutaneous gamma/delta T-cell lymphoma
Primary cutaneous marginal zone (MALT) lymphoma
T-cell follicular type lymphoma
Months
  
36 
4.5.2.  Required procedures to achieve a final diagnosis  
 
Figure 27. Required procedures to achieve a final diagnosis. Mycosis fungoides: 9 cutaneous biopsies, 1 
bone marrow biopsy and 1 FNA (Fine-needle aspiration); Primary cutaneous gamma/delta T-cell 
lymphoma: 6 cutaneous biopsies and 1 bone marrow biopsy; Primary cutaneous marginal zone (MALT) 
lymphoma: 1 cutaneous biopsy and 1 bone marrow biopsy ; T-cell follicular type lymphoma: 2 cutaneous 
biopsies, 1 bone marrow biopsy and 1 FNA (Fine-needle aspiration).  
As explained in the sections corresponding to each case, some of the lymphomas 
required several biopsies to reach a definitive diagnosis. It may happen, as in the case 
of mycosis fungoides, that it is necessary to perform several biopsies to verify the 
evolution of the disease or, as in the primary cutaneous gamma-delta T-cell lymphoma, 
to reach a diagnosis.  
In addition, in these cases other complementary tests, such as bone marrow biopsies 
or FNAs are usually necessary to rule out other diagnoses.  
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4.5.3. Inquiries made to external centers 
 
 Reference hospitals Reason for consultation 
Mycosis fungoides Valdecilla Hospital (Santander) Complementary morphological study  
Confirmation of diagnosis of mycosis fungoides 
Clinic Hospital (Barcelona)  Confirmation of diagnosis of mycosis fungoides 
transformed to large-cell lymphoma, CD30-  
Primary cutaneous 
gamma-delta T-cell 
lymphoma 
Salamanca Hospital Diagnostic compatibility with lupus panniculitis  
Valdecilla Hospital (Santander) Study of specific markers (CD3, CD56, 
Granzyme, Perforin, TCR gamma, Ki66, CD20, 
CD4, CD8, CD30, TCRBF1, PD1, EBV-LMP1 
and EBER) 
Confirmation of diagnosis of primary cutaneous 
gamma-delta T-cell lymphoma  
Primary cutaneous 
marginal zone (MALT) 
lymphoma 
 None.  
T-cell follicular type 
lymphoma 
Valdecilla Hospital (Santander) Study of special techniques  
Confirmation of diagnosis of nodal T-cell 
lymphoma with a T-follicular helper cell 
phenotype 
Table 2. Inquiries made to external centers. Mycosis fungoides: Valdecilla Hospital (Santander), Clinic 
Hospital (Barcelona); Primary cutaneous gamma/delta T-cell lymphoma: Salamanca Hospital, Valdecilla 
Hospital (Santander); Primary cutaneous marginal zone (MALT) lymphoma: none; T-cell follicular type 
lymphoma: Valdecilla Hospital (Santander) 
 
The need for confirmation or the application of specific markers by reference centers 
reflects the specificity and difficulty of these diagnoses.  
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5. DISCUSSION  
5.1. MYCOSIS FUNGOIDES 
With the clinical suspicion of cutaneous lymphoma due to the tumor lesion presented 
by the patient, among other differential diagnoses such as pseudolymphoma, 
squamous cell carcinoma, dermatofibrosarcoma or leiomyosarcoma, the initial 
performed biopsy showed a histologic morphology compatible with MF, the most 
frequent type of primary cutaneous lymphoma. Diffuse lymphoid infiltrate in the 
papillary dermis, epidermotropism and Pautrier's microabscesses were clear findings 
of the suspicion diagnosis and the latter, a pathognomonic sign, as exposed in the 
medical literature [3,4,5,6,7].  
In the successive biopsies of 2013 and 2014, morphological and immunohistochemical 
changes were observed, suggesting progression of the disease. Thus, the presence of 
isolated CD30+ cells has been observed in cases of indolent mycosis fungoides, but 
the increase in number of CD30+ cells has been related to advanced disease and is 
more frequently observed in late phases [5,6,7]; affectation of the subcutaneous cellular 
tissue in mycosis fungoides in tumor stage has been related to large cell transformed 
mycosis fungoides [6,7]. 
As described in several articles and described in biopsies analyzed after 2014, 
folliculotropic mycosis fungoides presented with an irregular lymphoid infiltrate that 
surrounded the follicles with a similar phenotype to that found in previous biopsies, 
which later presented mucinous degeneration. FMF in this case, which was derived 
from mycosis fungoides in tumor stage, has been associated with worse prognoses at 
5 years [4,5,7,8,9,35].  
In June 2015, due to the development of hilar and mediastinal lymphadenopathies, 
together with three pulmonary micronodules, forcing a distinction between sarcoidosis 
or dissemination of cutaneous lymphoma. In addition, new lesions that emerged during 
the same year revealed a granulomatous presentation. Kogut et al. described a case of 
granulomatous mycosis fungoides, a rare subtype of MF that is estimated to represent 
6,3 percent of cases [37]. Also, in older studies, Brincker described granulomatous 
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reactions in 7.3 percent of cases of non-Hodgkin lymphoma, most of them with a 
sarcoid presentation [38].  
In August 2015, after the development of new lesions in the abdomen, a change in the 
components of the lymphoid infiltrate was described in the biopsy performed, showing 
medium to large-sized cells and CD30 + expression in 40 percent of those, considering 
the diagnosis of mycosis fungoides transformed into a large cell lymphoma, CD30-. 
As exposed in the results section, transformation into a large cell lymphoma is defined 
as the presence of lymphocytes 4 times the size of a normal lymphocyte, present as 
micronodules or occupying more than 25 percent of the infiltrate. This transformation 
is indicative of an accelerated and more aggressive course, with decreased survival. 
Salhaney et al. described large oval nuclei, prominent and/or multiple nucleoli and 
moderate to abundant amphophilic cytoplasm. A certain degree of epidermotropism 
can be observed, as well as cerebriform cells scattered throughout the periphery of the 
transformed cells. In immunohistochemical analysis, a CD68+ phenotype was 
described, identifying a histiocytic component and excluding granulomatous mycosis 
fungoides; CD4+ is frequently found, with usual loss of panT-cell antigens, but CD8+ 
or CD4-/CD8- have also been observed. CD30+ cells may be seen, usually 
representing less than 75 percent of the infiltrate; if they exceed 75 percent of the 
infiltrate, it may be impossible to differentiate the transformed mycosis fungoides from 
a CD30 positive lymphoproliferative disorder arising in a patient with mycosis 
fungoides [3,7,8,9,10].  
The results of this review reflect the difficulty that exists in the diagnostic workup of 
mycosis fungoides, despite being the most frequent type of cutaneous. For years 
(2012-2015), histological diagnosis was changing, which led to the performance of 
numerous skin biopsies and inquiries to an external reference center in cutaneous 
lymphoma (Valdecilla Hospital, Santander).  Therefore, communication between both 
Pathology and Dermatology departments was essential.  
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5.2. PRIMARY CUTANEOUS GAMMA-DELTA T-CELL LYMPHOMA  
A sixty-five-year-old patient complained of a very nonspecific lesion, which appeared 
as an indurated erythematous plaque on the inner area of her left thigh, that was finally 
diagnosed as primary cutaneous gamma-delta T-cell lymphoma. Several studies 
coincide in the average age of diagnosis (60 years), as well as with the usual location 
of presentation of this lymphoma, the extremities [3,4,10,11,18,19,20]. Likewise, cases with 
psoriasis-like presentation have been described, with erythematous plaques that evolve 
later to ulcerated lesions [12], which is quite consistent with the clinical evolution of 
this patient. In September 2016, the patient started with symptoms of fever, sore throat 
and asthenia, which could be interpreted as accompanying B symptoms, also described 
in the articles reviewed in this paper [3,4,5,11,18,19,20].  
Histologic diagnosis of this lymphoma was complex, due to the successive initial 
biopsies that simulated other possible clinical conditions, such as septal panniculitis or 
lupus panniculitis. In the reviewed literature related to PCGD-TCL, the findings of 
mucin deposits or subcutaneous infiltrates with minimal atypia and histiocytosis are 
described as complications during the diagnostic workup [10], which can cause doubts 
precisely with the diagnoses identified in this case. Aguilera et. al describe in a Journal 
of the American Academy of Dermatology article published in 2007, a case in which 
a primary cutaneous gamma-delta T-cell lymphoma presented as a lupus panniculitis 
[17]. Another case was published in this same journal in 2018, in which a primary 
cutaneous gamma-delta T-cell lymphoma presented as a cytophagic histiocytic 
panniculitis, a rare and usually ulcerated type of panniculitis [22].  
Once a lymphoproliferative process was suspected, the studied biopsies could be 
confused with a subcutaneous panniculitis-like T-cell lymphoma [4,5,18,19,20], a 
lymphoma with a TCR ab- phenotype, and forced to include it as differential diagnosis 
of PCGD-TCL until subjecting the samples to specific markers that provide a 
definitive diagnosis. Willemze exposes in an article of 2017 the different features of 
lymphomas with panniculitic presentation, in which he includes the subcutaneous 
panniculitis-like T-cell lymphoma and the primary cutaneous gamma-delta T-cell 
lymphoma [19]. 
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Specific immunohistochemical analysis performed at the reference center, clarified the 
diagnosis, as positive markers typically found in PCGD-TCL, such as TCR gd, CD3, 
CD56, Granzyme B, perforin or TIA 1 were observed [3,4,5,10,11,18,19,20]. Molecular 
studies of the biopsies reviewed between November and December 2016 showed 
monoclonal rearrangement of the TCR genes, an expected finding in the study of this 
type of lymphoma [3,4,5,10,11,18,19,20].  
The exposed results reflect the complexity involved in arriving at a prompt and 
accurate diagnosis of a primary cutaneous gamma-delta T-cell lymphoma. The lack of 
availability of specific markers, the presence of TCR gd phenotype in some indolent 
lymphomas, as well as the inexperience in the interpretation of this type of infiltrates, 
have made this a challenging diagnosis. In these cases, correlation between 
morphological, immunophenotypic and molecular data is essential, but so is the 
clinical and pathological correlation to reach a definitive diagnosis in the shortest 
possible time.  
5.3. PRIMARY CUTANEOUS MARGINAL ZONE (MALT) LYMPHOMA  
An eighty-eight-year-old man consulted for presenting several pruritic, indurated, 
erythematous-violaceous lesions on the trunk, upper extremities and scalp that had 
lasted two months. Lesions presented in cases of primary cutaneous marginal zone 
(MALT) lymphoma are described as pruritic violaceous papules, plaques or nodules, 
that usually appear in the upper extremities [3,4,24,25,26], which correspond to those why 
the patient consulted.  
Histologic study of the biopsy corresponding to the first lesions showed a nodular, 
perivascular and perianexial lymphoid infiltrate, with exocytosis and isolated 
spongiosis without epidermotropism. The reviewed literature morphologically 
describes the PCMZL as a nodular or diffuse lymphocytic infiltrate in dermis, 
separated from the epidermis, that rarely shows colonization of follicular structures 
[3,4,5,24,25,26], which can be observed in other types of extranodal marginal zone 
lymphoma [25].  
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Immunophenotypic studies performed in the reference center to which the biopsy was 
sent, showed positivity for B-cell markers (CD20 and CD79a), as well as positivity 
for BCL2, orienting the diagnosis towards cutaneous B cell lymphoma, as described 
in reviews dedicated to this type of lymphoma [3,4,5,24,25]. In addition, clonal studies 
also indicated clonal rearrangement for the IgH gene, corresponding to B lymphoma 
[26]. 
The bone marrow study indicated infiltration by PCMZL, a necessary differential 
diagnosis from systemic lymphoma. Patients with cutaneous involvement due to a 
systemic marginal zone lymphoma tend to be older, and lesions preferentially occur in 
the head and neck. Morphological analysis is similar to other types of extranodal 
marginal zone lymphoma, but as said before, primary cutaneous marginal zone 
(MALT) lymphoma do not usually show infiltration of the follicles. Most marginal zone 
lymphomas express IgM, whereas primary cutaneous marginal zone (MALT) 
lymphoma usually expresses IgG, IgA or IgE [25].  
These results reflect how communication and joint approach of patients with cutaneous 
lymphoma by the services of Dermatology, Pathology and, in many cases, 
Hematology, is fundamental to reach an accurate diagnosis.  
5.4. T-CELL FOLLICULAR TYPE LYMPHOMA 
In this case, a sixty-year-old woman consulted the Dermatology department for 
generalized pruritus on the trunk, upper extremities and scalp, which had lasted for the 
past two years. Chronic pruritus in Dermatology consultations is possibly one of the 
challenges the clinician faces in daily life, since the range of pathologies in which it 
presents is very extensive, from banal to potentially aggressive diseases. In an article 
published in the New England Journal of Medicine in April 2013, chronic pruritus is 
associated with a marked reduction in quality of life, insomnia and mood alterations, 
including anxiety and depression. In this same study, possible causes of chronic 
pruritus are described, including dermatological and myeloproliferative disorders, and 
it is considered a priority to determine the underlying cause of chronic pruritus (Figure 
28) [39]. In addition to pruritus, the patient presented with splenomegaly and several 
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lymphadenopathies, all of it described in reviews about angioimmunoblastic T-cell 
lymphoma and/or T-cell follicular lymphoma [29,32].  
As stated in the results section, the first cytology performed of a submental lymph 
node in May 2017 was negative for malignant cells, which hindered the diagnosis 
workup. Later in July of that same year, the ganglion was removed and abundant 
microgranulomas of sarcoid type were observed, without necrosis and some 
eosinophils. In a reviewed article, it was described that neoplastic cells could go 
unnoticed, due to pronounced inflammatory background [29]. In this case, the presence 
of microgranulomas made the diagnosis hard, suggesting chronic non-necrotizing 
granulomatous lymphadenitis. It was with the clinical worsening of the patient, and 
after discussed in Dermatopathology session, when the possibility of a T-cell 
lymphoproliferative process was raised. Pujol et al. described four cases of patients 
diagnosed with nodal and/or extranodal non-Hodgkin lymphoma and 
angioimmunoblastic T-cell lymphoma who developed specific cutaneous involvement 
and prominent epithelioid cell and/or granulomatous inflammation [30]. In another of 
the reviewed articles, non-necrotizing granulomas are described as a possible 
presentation in chronic lymphocytic leukaemias, and specifies regarding the cutaneous 
presentation that granulomas may precede the histologic findings of lymphoma and 
can mimic non-necrotizing granulomatous entities [31].  
 
Figure 28. Diagnostic workup for chronic pruritus. Figure obtained from Yosipovitch G, Bernhard J. 
Chronic pruritus. N Engl J Med 2013; 368: 1629.  
clinical pr actice
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in the treatment of chronic itch, since histamine 
does not play a major role in conditions other 
than urticaria.25,32
Neuroactive Medications
Gabapentin and pregabalin, structural analogues 
of the neurotransmitter γ-aminobutyric acid, are 
effective for several types of pruritus. In controlled 
trials involving patients with pruritus caused by 
chronic kidney disease, low doses of gabapentin 
(100 to 300 mg three times a week) were signifi-
cantly more effective in reducing itch than pla-
cebo.33,34 Case reports have described the use of 
these drugs in practice to reduce neuropathic itch 
(e.g., postherpetic itch, brachioradial pruritus, and 
prurigo nodularis), although there are no data 
from controlled studies of these conditions.15,35
The mechanisms of action are unclear. The most 
frequent adverse effects are constipation, weight 
gain, drowsiness, ataxia, and blurred vision.
Antidepressants
Selective serotonin-reuptake inhibitors (e.g., par-
oxetine, sertraline, fluvoxamine, and fluoxetine) 
have been reported to reduce generalized pruri-
tus of various types, including but not limited to 
psychogenic itch, in case series.36 One small ran-
domized trial showed a modest antipruritic ef-
fect of paroxetine, as compared with placebo.37 A 
small double-blind trial demonstrated the effi-
cacy of sertraline (at a daily dose of 100 mg) for 
cholestatic itch.38 Case reports have also sug-
gested that the oral noradrenergic and specific 
serotonergic antidepressant mirtazapine (at a dai-
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The diagnostic suspicion was angioimmunoblastic T-cell lymphoma (AITL), the most 
frequent type of nodal T-cell lymphomas with a T-follicular helper-cell phenotype. T-
cell follicular type lymphoma is a very rare subtype, included in the WHO 
Classification in 2016, as a provisional entity, therefore, it is a lymphoma of which 
there is scarce clinical and pathological experience.  
6. CONCLUSIONS 
The aim of this review is to emphasize the difficulty of diagnosing this type of 
neoplasms, both on the clinical and on the histopathological side. All this has been 
reflected in the time elapsed from the first consultation of the patient to final diagnosis, 
the number of biopsies that each case required, the consultations made to external 
centers to confirm the diagnoses and the intervention of Dermatology, Pathology, 
Hematology and Radiology services, principally.  
For all these reasons, clinical and pathological correlation is crucial and should be 
materialized in the development of sessions, mainly between the Dermatology and 
Pathology departments, and the organization of interdisciplinary committees, in which 
the diagnosis of cutaneous lymphoma is addressed jointly.  
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